POSB20 Health Technology Assessment (HTA) of BRAF/MEK Inhibitors in Non-Resectable Metastatic BRAFV600 Melanoma Patients

Abstract

Authors

M Dimitrakopoulou A Kasselouris C Kani K Souliotis S Markantonis

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×